Truist Monetary upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) to a strong-buy score in a analysis report report printed on Monday,Zacks.com reviews.
GMAB has been the topic of numerous different analysis reviews. Wolfe Analysis started protection on Genmab A/S in a analysis report on Friday, March twenty seventh. They issued an “outperform” score and a $32.00 worth goal for the corporate. Wall Road Zen downgraded Genmab A/S from a “purchase” score to a “maintain” score in a analysis report on Saturday, February seventh. The Goldman Sachs Group upgraded shares of Genmab A/S from a “impartial” score to a “purchase” score in a report on Wednesday, April twenty second. BNP Paribas Exane upgraded shares of Genmab A/S from a “maintain” score to a “strong-buy” score in a report on Wednesday, April twenty second. Lastly, Morgan Stanley began protection on shares of Genmab A/S in a report on Monday, February sixteenth. They issued an “equal weight” score and a $34.00 goal worth for the corporate. Two analysts have rated the inventory with a Robust Purchase score, seven have given a Purchase score and three have issued a Maintain score to the inventory. Based on information from MarketBeat, the inventory presently has a consensus score of “Reasonable Purchase” and a median goal worth of $39.36.
Get Our Newest Analysis Report on Genmab A/S
Genmab A/S Worth Efficiency
Shares of NASDAQ:GMAB opened at $26.11 on Monday. Genmab A/S has a one 12 months low of $18.89 and a one 12 months excessive of $35.43. The enterprise’s fifty day shifting common worth is $27.48 and its two-hundred day shifting common worth is $30.09. The corporate has a debt-to-equity ratio of 0.86, a fast ratio of two.01 and a present ratio of two.02. The inventory has a market cap of $16.78 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 1.20 and a beta of 0.97.
Genmab A/S (NASDAQ:GMAB – Get Free Report) final introduced its quarterly earnings information on Wednesday, February 18th. The corporate reported $0.05 EPS for the quarter, lacking analysts’ consensus estimates of $0.46 by ($0.41). The enterprise had income of $1.06 billion throughout the quarter, in comparison with analysts’ expectations of $1.06 billion. Genmab A/S had a internet margin of 25.89% and a return on fairness of 17.35%. On common, analysts forecast that Genmab A/S will publish 1.18 EPS for the present fiscal 12 months.
Institutional Inflows and Outflows
A lot of hedge funds and different institutional traders have lately added to or diminished their stakes within the firm. Built-in Advisors Community LLC acquired a brand new place in Genmab A/S within the first quarter valued at $205,000. AdvisorShares Investments LLC boosted its holdings in Genmab A/S by 2.2% within the first quarter. AdvisorShares Investments LLC now owns 30,853 shares of the corporate’s inventory valued at $828,000 after buying a further 653 shares over the last quarter. V Sq. Quantitative Administration LLC acquired a brand new place in Genmab A/S within the first quarter valued at $34,000. QRG Capital Administration Inc. boosted its holdings in Genmab A/S by 7.4% within the first quarter. QRG Capital Administration Inc. now owns 65,822 shares of the corporate’s inventory valued at $1,766,000 after buying a further 4,561 shares over the last quarter. Lastly, Y Intercept Hong Kong Ltd acquired a brand new place in Genmab A/S within the first quarter valued at $1,198,000. Institutional traders and hedge funds personal 7.07% of the corporate’s inventory.
Genmab A/S Firm Profile
(Get Free Report)
Genmab A/S is a Denmark-based biotechnology firm specializing within the discovery and improvement of antibody therapeutics for the remedy of most cancers. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has constructed a sturdy analysis platform targeted on harnessing novel antibody engineering applied sciences to create next-generation therapies. The corporate’s work facilities on figuring out targets in hematologic malignancies and stable tumors, advancing its proprietary molecules from early discovery by means of medical improvement.
Genmab’s portfolio consists of merchandise developed in collaboration with main world pharmaceutical companions.
Featured Tales
5 shares we like higher than Genmab A/S
